Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders
June 24, 2022 16:15 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., June 24, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...
Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma
June 20, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., June 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven...
Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress™ 2022
June 15, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
- Hepion Represented as Authors in Preclinical and Clinical Posters Related to Rencofilstat and Cyclophilins – EDISON, N.J., June 15, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc....
Hepion Pharmaceuticals Appoints Accomplished Life Sciences Industry Veteran, Dr. Launa J. Aspeslet, as Chief Operating Officer
June 14, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
- Dr. Aspeslet joins the Company to support rencofilstat’s clinical program - EDISON, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...
Hepion Pharmaceuticals Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting
May 31, 2022 16:30 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
CORRECTING and REPLACING - Hepion Pharmaceuticals, Inc.
May 27, 2022 08:54 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- In the press release issued earlier today by Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), we've been informed by the company that in both the headline...
Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH Congress
May 27, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial
May 03, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
- HepQuant Evaluation Offers Sensitive Measurement of Hepatic Function and Correlation with Clinical Outcomes - - Dedicated Phase 2b Trial Supports Overarching NASH Program for Rencofilstat - -...
Hepion Pharmaceuticals to Present at the Q1 Investor Summit Conference
March 07, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Appoints World-Renowned Hepatologist, Dr. Eddie C. Cheung, to Lead the Company’s Strategic Medical Affairs in Asia
February 15, 2022 08:00 ET
|
Hepion Pharmaceuticals, Inc.
- Dr. Cheung, who has dedicated his career to NASH, hepatocellular carcinoma, fatty liver disease, and viral hepatitis will endeavor to advance Hepion’s business development and partnering efforts in...